Clinical Characteristics and Prognosis of 218 Patients With COVID-19: A Retrospective Study Based on Clinical Classification

Yan, Xiquan; Han, Xiaotong; Peng, Danhong; Fan, Yong; Fang, Zhixiong; Long, Da; Xie, Yong; Zhu, Shuibo; Chen, Fang; Lin, Wei; Zhu, Yimin

doi:10.3389/fmed.2020.00485

Cited by 40 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients with more severe disease course had higher temperature, lower blood oxygen saturation, lower eosinophils count, higher ESR, higher CRP and creatinine levels, lower GFR, and higher levels of LDH and troponin T on admission to the hospital than patients with milder disease course. In general, these results concur with previous studies [1, 5, 6, 7, 8, 11]. However, some findings should be discussed in greater detail.…”

Section: Discussionsupporting

confidence: 92%

“…Our study also demonstrated the relationship between COVID-19 severity and reduced renal function. It contrasts with Feng et al [1] and Yan X. et al [11], who revealed no differences in this function. In our study, the level of creatinine was significantly higher in the group with severe disease course than in groups with mild or moderate disease course.…”

Section: Discussioncontrasting

confidence: 76%

See 1 more Smart Citation

Clinical characteristics of COVID-19 patients in Latvia under low incidence in Spring 2020

Vīksna

Koļesova

Kolesovs

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCOVID-19 is a new infectious disease with severe disease course and high mortality in some groups. Blood tests on admission to the hospital can be useful for stratification of patients and timely correction. Our study investigated the clinical features of COVID-19 patients in Latvia and differences in blood tests in groups with different disease severity.MethodsThe retrospective study included 100 patients hospitalized in Riga East Clinical University Hospital in Spring 2020. The severity of the disease course was classified by the presence of pneumonia and its combination with respiratory failure. We have assessed blood cells’ count, hemoglobin, hematocrit, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), alanine aminotransferase, lactate dehydrogenase (LDH), troponin T, electrolytes, creatinine, glomerular filtration rate (GFR), D-dimer, prothrombin time, prothrombin index, oxygen saturation, and temperature on admission to the hospital.ResultsPatients were from 18 to 99 (57±18 years, 57% males). Comorbidities were found in 74% of patients. The mild, moderate, and severe groups included 35, 44, and 16 patients, respectively. In the severe group, the mortality rate was 50%. The progression to severe COVID-19 was associated positively with temperature, ESR, CRP, creatinine, LDH, and troponin T and negatively associated with oxygen saturation, eosinophils, and GFR on admission to the hospital.ConclusionsCOVID-19 severity associates with lower renal function and a higher level of inflammation and tissue damage. Eosinophils, CRP, ESR, LDH, troponin T, creatinine, and GFR are blood indicators for monitoring patients’ condition.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 76%

Clinical characteristics of COVID-19 patients in Latvia under low incidence in Spring 2020

Vīksna

Koļesova

Kolesovs

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The 136 studies, which involved 102,345 patients, included 97 observational studies, 11 case series, five letters, one application note, 13 randomized trials, one pilot study, five reports, one non-randomized trial, one short communication, and one correspondence. The countries involved in these studies included China (51 studies ( Cai et al, 2020 ; Cao et al, 2020a ; Cao et al, 2020b ; Chen et al, 2020a ; Chen et al, 2020b ; Chen et al, 2020c ; Chen et al, 2020d ; Chen Jun et al, 2020 ; Deng et al, 2020 ; Hu et al, 2020a ; Hu et al, 2020b ; Huang et al, 2020a ; Huang et al, 2020b ; Huang et al, 2020c ; Hung et al, 2020 ; Jiang et al, 2020 ; Li et al, 2020a ; Li et al, 2020b ; Lian et al, 2020a ; Lian et al, 2020b ; Liu et al, 2020a ; Liu et al, 2020b ; Liu et al, 2020c ; Liu et al, 2020d ; Mo et al, 2020 ; Ouyang et al, 2020 ; Pan et al, 2020 ; Shi et al, 2020 ; Tang et al, 2020 ; Wang et al, 2020a ; Wang et al, 2020b ; Wang et al, 2020d ; Wang et al, 2020e ; Wu et al, 2020a ; Wu et al, 2020b ; Wu et al, 2020c ; Xu et al, 2020a ; Xu et al, 2020b ; Xu et al, 2020c ; Yan et al, 2020a ; Yan et al, 2020b ; Yang et al, 2020 ; Yu et al, 2020a ; Yu et al, 2020b ; Zhang et al, 2020a ; Zhang et al, 2020b ; Zhang et al, 2020c ; Zhao et al, 2020 ; Zheng et al, 2020 ; Zhou et al, 2020 ; Zhu et al, 2020 )), the United States (31 studies ( Alam et al, 2020 ; Bhatraj...…”

Section: Resultsmentioning

confidence: 99%

“…We used the general term “relative risk” to refer to the mortality risk. A total of 16 observational studies ( Berenguer et al, 2020 ; Cao et al, 2020b ; Catteau et al, 2020 ; Ferrando et al, 2020 ; Gupta et al, 2020 ; Krishnan et al, 2020 ; Lee et al, 2020a ; Morrison et al, 2020 ; Nowak et al, 2020 ; Okoh et al, 2020 ; Primmaz et al, 2020 ; Salacup et al, 2020 ; Wang et al, 2020a ; Yan et al, 2020b ; Zerah et al, 2020 ; Zhou et al, 2020 ) were involved in this assessment. We extracted the number of patients who died from COVID-19 following a certain treatment.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: Limited data on the efficacy and safety of currently applied COVID-19 therapeutics and their impact on COVID-19 outcomes have raised additional concern.Objective and Methods: To estimate the efficacy and safety of COVID-19 therapeutics, we performed meta-analyses of the studies reporting clinical features and treatments of COVID-19 published from January 21 to September 6, 2020.Results: We included 136 studies that involved 102,345 COVID-19 patients. The most prevalent treatments were antibiotics (proportion: 0.59, 95% CI: [0.51, 0.67]) and antivirals (proportion: 0.52, 95% CI: [0.44, 0.60]). The combination of lopinavir/ritonavir and Arbidol was the most effective in treating COVID-19 (standardized mean difference (SMD) = 0.68, 95% CI: [0.15, 1.21]). The use of corticosteroids was associated with a small clinical improvement (SMD = −0.40, 95% CI: [−0.85, −0.23]), but with a higher risk of disease progression and death (mortality: RR = 9.26, 95% CI: [4.81, 17.80]; hospitalization length: RR = 1.54, 95% CI: [1.39, 1.72]; severe adverse events: RR = 2.65, 95% CI: [2.09, 3.37]). The use of hydroxychloroquine was associated with a higher risk of death (RR = 1.68, 95% CI: [1.18, 2.38]). The combination of lopinavir/ritonavir, ribavirin, and interferon-β (RR = 0.34, 95% CI: [0.22, 0.54]); hydroxychloroquine (RR = 0.58, 95% CI: [0.39, 0.58]); and lopinavir/ritonavir (RR = 0.72, 95% CI: [0.56, 0.91]) was associated with reduced hospitalization length. Hydrocortisone (RR = 0.05, 95% CI: [0.03, 0.10]) and remdesivir (RR = 0.74, 95% CI: [0.62, 0.90]) were associated with lower incidence of severe adverse events. Dexamethasone was not significant in reducing disease progression (RR = 0.45, 95% CI: [0.16, 1.25]) and mortality (RR = 0.90, 95% CI: [0.70, 1.16]). The estimated combination of corticosteroids with antivirals was associated with a better clinical improvement than antivirals alone (SMD = −1.09, 95% CI: [−1.64, −0.53]).Conclusion: Antivirals are safe and effective in COVID-19 treatment. Remdesivir cannot significantly reduce COVID-19 mortality and hospitalization length, while it is associated with a lower incidence of severe adverse events. Corticosteroids could increase COVID-19 severity, but it could be beneficial when combined with antivirals. Our data are potentially valuable for the clinical treatment and management of COVID-19 patients.

show abstract

“…The clinical course of the COVID-19 is highly variable, ranging from asymptomatic infection to respiratory failure, multi-organ dysfunction, and mortality. Apart from the respiratory system, COVID-19 is also associated with hazardous effects on other body systems [1,2]. Several studies have underlined that older patients and patients with comorbidities are more susceptible to COVID-19, its more serious complications, and progression to severe disease.…”

Section: Introductionmentioning

confidence: 99%

The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis

Menon¹,

Sharma²,

Kataria³

et al. 2021

Cureus

View full text Add to dashboard Cite

Background and objective The coronavirus disease 2019 (COVID-19) pandemic has become a global healthcare emergency. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has a wide range of clinical manifestations ranging from subclinical infection to multi-organ failure. In addition to the respiratory system, COVID-19 also adversely affects the kidneys. In this study, we aimed to measure the prevalence of acute kidney injury (AKI) in COVID-19 and its association with the disease severity and mortality in COVID-19 patients. Materials and methods We conducted our study by following the Preferred Reporting Items for Systematic Review and Metaanalyses (PRISMA) guidelines. A comprehensive literature search using four databases (PubMed, EMBASE, Google Scholar, and clinicaltrial.gov) was performed. Our initial search returned 2,771 articles. After excluding review articles, duplicates, and non-relevant studies, we included 20 articles that reported an association between COVID-19 and AKI. We subsequently performed a random effect analysis to find the pooled prevalence, pooled odds ratio (OR) estimates, and 95% confidence intervals for severe COVID-19 and mortality outcomes in AKI using Cochrane RevMan (version 5.4) and R programming language (version 4.16-2). Results A total of 14,415 patients from various countries were included. Among the 20 cohorts, the median age was 55.8 ±8.39 years (range: 43-72 years), and 43.78% of the subjects were female. Out of a total of 14,415 patients, 3,820 developed AKI with a pooled prevalence of 11% (95% CI: 0.07-0.15; p<0.01; I 2 =98%). AKI was found to have a significant association with severe COVID-19 disease, with a pooled OR of 8.45 (95% CI: 5.56-12.56; p<0.00001; I 2 =0%). AKI was associated with significantly higher mortality in patients with COVID-19 with an OR of 13.52 (95% CI: 5.43-33.67; p<0.00001; I 2 =88%). Conclusion AKI manifests as a common COVID-19 complication, and COVID-19 patients with AKI generally have poor outcomes in terms of disease severity and mortality.

show abstract

Clinical Characteristics and Prognosis of 218 Patients With COVID-19: A Retrospective Study Based on Clinical Classification

Cited by 40 publications

References 38 publications

Clinical characteristics of COVID-19 patients in Latvia under low incidence in Spring 2020

Clinical characteristics of COVID-19 patients in Latvia under low incidence in Spring 2020

Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

The Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About